Loading
ST
Sigilon Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ELI LILLY & Co, was filed 14 Aug 2023.
Sigilon Therapeutics, Inc.: what insiders have been doing
Sigilon Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Sigilon Therapeutics, Inc. has published a filing in the past twelve months. The most recent one dates from 15 August 2023.
Over the whole record (from 2020), the tally stands at 2 purchases and 2 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
22
Thresholds
n/a
Buy Volume
€28M
2 ops. · all time
Sell Volume
€2M
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$11.1M
Net income-US$37.5M-336.5% margin
Last declaration on 15 August 2023
Declarations22 total
113,960 shares@ US$14.9214.3% of flowCommon StockSEC:0000899243-23-018154:1
683,760 shares@ US$14.9285.7% of flowCommon StockSEC:0000899243-23-018154:0
1,718,493 shares@ US$14.92100.0% of flowCommon StockSEC:0000899243-23-018115:0
Canonical exit: 9 Nov 2023 (T+90)
2,884 sharesCommon StockSEC:0001415889-23-012128:0
12,169 sharesCommon StockSEC:0001415889-23-012127:0
1,925 sharesCommon StockSEC:0001415889-23-012133:0
3,504 sharesCommon StockSEC:0001415889-23-012126:0
341 sharesCommon StockSEC:0001415889-23-012134:0
2,884 shares@ US$19.24100.0% of flowCommon StockSEC:0001415889-23-011523:0
1,444 shares@ US$19.24100.0% of flowCommon StockSEC:0001415889-23-011447:0
5,528 shares@ US$19.24100.0% of flowCommon StockSEC:0001415889-23-011446:0
50,000 shares0Common StockSEC:0001415889-21-005084:0
11,500 shares0Common StockSEC:0001415889-21-004690:0
6,750 shares@ US$10.3694.8% of flowCommon StockSEC:0001415889-21-003398:1
6,750 shares@ US$0.57100.0% of flowCommon StockSEC:0001415889-21-003398:0
200,000 shares@ US$10.00100.0% of flowCommon StockSEC:0001415889-21-002817:0
300,000 shares@ US$18.0016.0% of flowCommon StockSEC:0000059478-20-000187:1
Canonical exit: 8 Mar 2021 (T+90)
8,888,888 sharesCommon StockSEC:0001104659-20-134302:0
1,481,481 sharesCommon StockSEC:0001104659-20-134302:1
2,444,443 sharesCommon StockSEC:0000059478-20-000187:0
4,444 sharesCommon StockSEC:0001104659-20-134300:0
22,222 sharesCommon StockSEC:0001104659-20-134299:0
22 of 22 declarations
About Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc. was a U.S.-based biotechnology company that was listed on the NASDAQ market in the United States (United States) and focused on encapsulated cell therapies designed to address chronic diseases with the goal of delivering a potential functional cure. The company was founded in 2015 by Flagship Pioneering together with academic co-founders, adopted the Sigilon Therapeutics name in 2017, and was headquartered in Cambridge, Massachusetts, within the Boston biopharma cluster. Its core thesis centered on a biomedical technology platform and cell-therapy approach intended to shield therapeutic cells from host immune detection and foreign body responses so they could produce deficient therapeutic proteins or other molecules over long periods.
Operationally, Sigilon’s most visible work centered on chronic disease applications, especially type 1 diabetes. Its lead strategic program was SIG-002, an encapsulated cell therapy candidate developed in collaboration with Eli Lilly. The company’s platform combined advanced cell engineering with biocompatible materials, positioning it as an early-stage, science-driven biotech rather than a commercial-stage pharmaceutical business. Its value proposition was therefore tied to translational success: proving clinical efficacy, demonstrating safety and durability, manufacturing at scale, and eventually navigating regulatory approval. That profile also made the company highly dependent on capital markets and strategic partnerships.
Read moreShow less
From a competitive standpoint, Sigilon operated in a specialized but important segment of regenerative medicine and metabolic disease innovation. Its potential differentiation lay in the ability to create an implantable or encapsulated cell system that could provide sustained therapeutic output without chronic immunosuppression. However, the company faced the same structural challenges common to platform biotechs: scientific uncertainty, clinical execution risk, regulatory complexity, and competition from both large pharmaceutical companies and other cell/gene therapy developers pursuing diabetes and chronic-disease solutions. As a result, the investment case was primarily based on platform optionality and the likelihood of strategic validation rather than near-term revenue generation.
A major recent development reshaped the company’s market status. Eli Lilly announced its acquisition of Sigilon in 2023 and completed the transaction in August 2023, after which Sigilon became a wholly owned Lilly subsidiary. In practical terms, Sigilon no longer trades as an independent public equity under SGTX, but its history remains relevant for reviewing legacy SEC disclosures, including Form 4 insider transaction filings and earlier clinical-development milestones. For investors, especially those following U.S. biotech M&A, Sigilon is best understood as a former NASDAQ-listed innovation platform that was ultimately absorbed into a major pharmaceutical group rather than as a continuing standalone public company.
